Cargando…

Correction to: Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine

Detalles Bibliográficos
Autor principal:	Blair, Hannah A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374713/ https://www.ncbi.nlm.nih.gov/pubmed/37402082 http://dx.doi.org/10.1007/s40263-023-01019-2

Ejemplares similares

Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
por: Blair, Hannah A.
Publicado: (2023)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials
por: Gao, Bixi, et al.
Publicado: (2020)

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
por: Polavieja, Pepa, et al.
Publicado: (2022)

Clinical efficacy and safety of rimegepant in the treatment of migraine: a meta-analysis of randomized controlled trials
por: Wang, Qinghui, et al.
Publicado: (2023)

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
por: Johnston, Karissa M, et al.
Publicado: (2022)

Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)
por: Powell, Lauren C., et al.
Publicado: (2022)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant
por: Johnston, Karissa M., et al.
Publicado: (2021)

Correction: Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study
por: Pascual, Julio, et al.
Publicado: (2023)

Correction to: Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis
por: Zhao, Xiuyuan, et al.
Publicado: (2021)

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
por: Popoff, Evan, et al.
Publicado: (2021)

Antagonism of CGRP Signaling by Rimegepant at Two Receptors
por: Pan, Kylie S., et al.
Publicado: (2020)

Correction to: OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

Is the right way to go in between?: Rimegepant as needed provides preventive benefit. A comment on: monthly migraine days, tablet utilization, and quality of life associated with rimegepant—post hoc results from an open label safety study (BHV3000–201)
por: Gantenbein, Andreas R., et al.
Publicado: (2023)

Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
por: Ailani, Jessica, et al.
Publicado: (2023)

Correction to: Remdesivir: A Review in COVID-19
por: Blair, Hannah A.
Publicado: (2023)

Correction to: Secukinumab: A Review in Ankylosing Spondylitis
por: Blair, Hannah A.
Publicado: (2019)

Correction to: Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Correction to: Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Use of Rimegepant in the Management of Cervicogenic Headache Secondary to Trauma: A Case Series
por: Zaw, Shin T, et al.
Publicado: (2023)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

The acute and preventative treatment of episodic migraine
por: Miller, Sarah
Publicado: (2012)

Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Correction to: Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

Correction to: Dapaglifozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
por: Blair, Hannah A.
Publicado: (2021)

Gepants for Acute and Preventive Migraine Treatment: A Narrative Review
por: Rissardo, Jamir Pitton, et al.
Publicado: (2022)

Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Correction to: Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
por: Nie, Tina, et al.
Publicado: (2022)

Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)
por: Johnston, Karissa, et al.
Publicado: (2022)

Correction to: Hexanic Extract of Serenoa repens (Permixon(®)): A Review in Symptomatic Benign Prostatic Hyperplasia
por: Blair, Hannah A.
Publicado: (2022)

Correction to: The clinician’s guide to prevention and treatment of osteoporosis
por: LeBoff, M. S., et al.
Publicado: (2022)

Correction to: Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review
por: Holtan, Shernan G., et al.
Publicado: (2022)

Correction: Economic burden of chronic migraine in OECD countries: a systematic review
por: Eltrafi, Alyaa, et al.
Publicado: (2023)

Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating Women
por: Baker, Teresa E., et al.
Publicado: (2022)

Correction to: Dexamethasone Intracanalicular Insert: A Review in Treating Post-Surgical Ocular Pain and Inflammation
por: Lee, Arnold, et al.
Publicado: (2020)

Correction to: Ritlecitinib: First Approval
por: Blair, Hannah A.
Publicado: (2023)

Correction to: Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)

Correction to: Belumosudil: First Approval
por: Blair, Hannah A.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_npge3od51juthb597eu4ke0cpj